A Phase 2 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 13 sites in 3 countries. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-07-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 15th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 2nd registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 40 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 5 in phase 2, and was the 2nd registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo
Drug: Placebo
tadalafil
Drug: Tadalafil
20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
Also known as: LY450190, Cialis, IC351
Placebo tablet taken by mouth once a day for 12 weeks.
Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax)
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Free-Flow Studies
Qmax was measured during free-flow tests using a standard calibrated flow meter.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Free-Flow Studies
Qave was measured during free-flow tests using a standard calibrated flow meter.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Free-Flow Studies
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Postvoid Residual Volume (PVRcath) Measured During Free-Flow Studies
PVRcath is the volume of urine remaining int he bladder after voiding, measured by catheterization.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Total Bladder Capacity Measured During Free-Flow Studies
Total bladder capacity was defined as Vcomp + PVRcath (obtained when the bladder was full).
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Bladder Voiding Efficiency (BVE) Measured During Free-Flow Studies
Bladder voiding efficiency was defined as (Vcomp/total bladder capacity) X 100 (obtained when the bladder was full).
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Pressure-Flow Studies
Qmax was measured duirng pressure-flow tests.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Pressure-Flow Studies
Qave was measured during pressure-flow tests.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Pressure-Flow Studies
Vcomp was defined as the volume of voided urine measured during pressure-flow tests.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Maximum Detrusor Pressure (Max Pdet) Measured During Pressure-Flow Studies
Max Pdet was defined as the maximum detrusor pressure observed during voiding.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Bladder Contractility Index (BCI) Measured During Pressure-Flow Studies
BCI was derived from the equation PdetQmax + 5Qmax. Scores: \<100 means weak, 100-150 menas normal, \>150 means strong. A decrease means a decrease in contractility of the bladder.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Bladder Outlet Obstruction Index (BOOI) Measured During Pressure-Flow Studies
BOOI, formerly known as the Abrams-Griffith number, was derived from the equation PdetQmax - 2Qmax. Scores: \<20 means unobstructed, 20-40 means equivocol, \>40 means obstructed. An increase means worsening of obstruction, a decreased means lessening of obstruction (improvement).
Time frame: Baseline and 12 weeks
Presence of Involuntary Detrusor Contractions During Bladder Filling
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in Bladder Volume at First Involuntary Detrusor Contraction
Assessed in participants with involuntary detrusor contractions during the bladder filling at both baseline and endpoint.
Time frame: Baseline and 12 weeks
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score
The IPSS Total Score is obtained by combining the scores of the responses to the 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Time frame: 12 weeks
Clinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests
Laboratory tests that were statistically significant and clinically adverse would be reported for safety.
Time frame: Baseline and 12 weeks
| Milestone | Placebo | Tadalafil |
|---|---|---|
| Started | 101 | 99 |
| Completed | 92 | 89 |
| Not completed | 9 | 10 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Entry criteria not met | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 5 | 4 |
| centimeters of water (cm H20) | Placebo | Tadalafil |
|---|---|---|
| Baseline | 54.83 ± 27.36 | 56.87 ± 29.67 |
| Change from Baseline to 12 Week Endpoint | 1.92 ± 19.71 | -2.95 ± 15.92 |
Qmax was measured during free-flow tests using a standard calibrated flow meter.
| milliliters per second | Placebo | Tadalafil |
|---|---|---|
| Baseline | 13.03 ± 7.34 | 14.75 ± 10.70 |
| Change from Baseline to 12 Week Endpoint | 0.52 ± 7.83 | 0.01 ± 8.83 |
Qave was measured during free-flow tests using a standard calibrated flow meter.
| millilters per second | Placebo | Tadalafil |
|---|---|---|
| Baseline | 7.10 ± 4.37 | 7.23 ± 4.18 |
| Change from Baseline to 12 Week Endpoint | -0.01 ± 4.11 | 1.00 ± 3.04 |
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline | 258.56 ± 134.21 | 268.22 ± 149.77 |
| Change from Baseline to 12 Week Endpoint | -4.10 ± 151.82 | -5.17 ± 151.73 |
PVRcath is the volume of urine remaining int he bladder after voiding, measured by catheterization.
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline | 59.62 ± 66.74 | 48.99 ± 65.73 |
| Change from Baseline to 12 Week Endpoint | -1.85 ± 80.92 | -9.13 ± 70.36 |
Total bladder capacity was defined as Vcomp + PVRcath (obtained when the bladder was full).
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline | 327.95 ± 165.66 | 316.79 ± 187.31 |
| Change from Baseline to 12 Week Endpoint | -17.53 ± 182.62 | -14.88 ± 187.10 |
Bladder voiding efficiency was defined as (Vcomp/total bladder capacity) X 100 (obtained when the bladder was full).
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline | 84.01 ± 14.56 | 85.85 ± 13.44 |
| Change from Baseline to 12 Week Endpoint | -0.52 ± 16.31 | 1.85 ± 16.22 |
Qmax was measured duirng pressure-flow tests.
| milliliters per second | Placebo | Tadalafil |
|---|---|---|
| Baseline | 9.49 ± 4.90 | 10.29 ± 4.46 |
| Change from Baseline to 12 Week Endpoint | 0.50 ± 2.91 | 0.38 ± 2.92 |
Qave was measured during pressure-flow tests.
| milliliters per second | Placebo | Tadalafil |
|---|---|---|
| Baseline | 4.67 ± 2.44 | 5.50 ± 2.68 |
| Change from Baseline to 12 Week Endpoint | 0.45 ± 1.66 | 0.58 ± 1.91 |
Vcomp was defined as the volume of voided urine measured during pressure-flow tests.
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline | 294.10 ± 147.74 | 296.64 ± 143.30 |
| Change from Baseline to 12 Week Endpoint | 3.31 ± 140.46 | 13.51 ± 99.64 |
Max Pdet was defined as the maximum detrusor pressure observed during voiding.
| centimeters of water (cm H20) | Placebo | Tadalafil |
|---|---|---|
| Baseline | 67.13 ± 31.66 | 72.20 ± 38.65 |
| Change from Baseline to 12 Week Endpoint | -0.48 ± 28.19 | -2.11 ± 24.08 |
BCI was derived from the equation PdetQmax + 5Qmax. Scores: \<100 means weak, 100-150 menas normal, \>150 means strong. A decrease means a decrease in contractility of the bladder.
| units on a nomogram | Placebo | Tadalafil |
|---|---|---|
| Baseline | 102.28 ± 32.84 | 108.32 ± 32.14 |
| Change from Baseline to 12 Week Endpoint | 4.43 ± 20.86 | -1.04 ± 20.37 |
BOOI, formerly known as the Abrams-Griffith number, was derived from the equation PdetQmax - 2Qmax. Scores: \<20 means unobstructed, 20-40 means equivocol, \>40 means obstructed. An increase means worsening of obstruction, a decreased means lessening of obstruction (improvement).
| units on a nomogram | Placebo | Tadalafil |
|---|---|---|
| Baseline | 35.84 ± 30.87 | 36.28 ± 33.14 |
| Change from Baseline to 12 Week Endpoint | 0.92 ± 22.10 | -3.71 ± 17.56 |
| participants | Placebo | Tadalafil |
|---|---|---|
| Present at Baseline | 33 | 28 |
| Not Present at Baseline | 58 | 56 |
| Present at Endpoint | 36 | 31 |
| Not Present at Endpoint | 55 | 53 |
| Present at Both Baseline and Endpoint | 22 | 18 |
| Present at Baseline Only | 11 | 10 |
| Present at Endpoint Only | 14 | 13 |
| Present at Neither Baseline nor Endpoint | 44 | 43 |
Assessed in participants with involuntary detrusor contractions during the bladder filling at both baseline and endpoint.
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline | 120.55 ± 82.50 | 164.00 ± 108.31 |
| Change from Baseline to 12 Week Endpoint | 27.86 ± 128.20 | 28.56 ± 106.67 |
The IPSS Total Score is obtained by combining the scores of the responses to the 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Baseline | 22.01 ± 5.72 | 21.46 ± 5.63 |
| Change from Baseline to 12 Week Endpoint | -5.04 ± 6.93 | -9.13 ± 6.90 |
Laboratory tests that were statistically significant and clinically adverse would be reported for safety.
| significant and clinically adverse labs | Placebo | Tadalafil |
|---|---|---|
| Clinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests | 0 ± 0.41 | 0 ± 0.33 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | — | — |
| Tadalafil | — | — | — |
| Event | Placebo | Tadalafil |
|---|---|---|
| CellulitisInfections and infestations | 0/101 | 1/99 |
| PneumoniaInfections and infestations | 0/101 | 1/99 |
| Humerus fractureInjury, poisoning and procedural complications | 0/101 | 1/99 |
| Skin lacerationInjury, poisoning and procedural complications | 0/101 | 1/99 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 0/101 | 1/99 |
| Myocardial infarction/DeathCardiac disorders | 1/101 | 0/99 |
| HypoaesthesiaNervous system disorders | 1/101 | 0/99 |
| Event | Placebo | Tadalafil |
|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/101 | 8/99 |
| HeadacheNervous system disorders | 3/101 | 7/99 |
| Back painMusculoskeletal and connective tissue disorders | 3/101 | 5/99 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/101 | 3/99 |
| DizzinessNervous system disorders | 3/101 | 0/99 |
| GastritisGastrointestinal disorders | 0/101 | 2/99 |
| InfluenzaInfections and infestations | 1/101 | 2/99 |
| Upper respiratory tract infectionInfections and infestations | 2/101 | 2/99 |
| Hepatic enzyme increasedInvestigations | 0/101 | 2/99 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/101 | 2/99 |
| Age Continuous(years) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 59.03 ± 9.69 | 58.16 ± 8.82 | 58.60 ± 9.26 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 101 | 99 | 200 |
| Region of Enrollment(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| United States | 99 | 95 | 194 |
| Canada | 2 | 4 | 6 |
| Baseline Benign Prostatic Hyperplasia (BPH) Lower Urinary Tract Symptom (LUTS) Severity(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Moderate (IPSS <20) | 34 | 35 | 69 |
| Severe (IPSS ≥20) | 66 | 62 | 128 |
| Missing Baseline Measure | 1 | 2 | 3 |
| Bladder Outlet Obstruction Index (BOOI)(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Obstructed (BOOI > 40) | 33 | 34 | 67 |
| Equivocal (BOOI 20-40) | 35 | 34 | 69 |
| Unobstructed (BOOI < 20) | 33 | 31 | 64 |
| Duration of Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms (BPH LUTS)(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| 6 months to 1 year | 13 | 12 | 25 |
| 1 year to 3 years | 36 | 30 | 66 |
| > 3 years | 52 | 57 | 109 |
| Erectile Dysfunction Severity(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mild | 20 | 22 | 42 |
| Moderate | 31 | 31 | 62 |
| Severe | 9 | 5 | 14 |
| Presence of Erectile Dysfunction(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Yes | 60 | 58 | 118 |
| No | 41 | 41 | 82 |
8 further baseline measures are reported on the registry.
The record gives a start of Oct 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil